Long-term efficacy of rimonabant in improving glucose tolerance in overweight/obese non-diabetic patients: 2-year results from RIO-Europe

被引：0
|
作者：
Scheen, Andre J.
Van Gaal, Luc
机构：
来源：
DIABETES | 2008年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A31 / A31
页数：1
相关论文
共 50 条
  • [1] Rimonabant improves glucose tolerance in the overweight or obese non-diabetic patient:: analysis of the RIO-Europe and RIO-Lipids studies
    Scheen, A.
    Despres, J. P.
    Ziegler, O.
    Golay, A.
    Van Gaal, L.
    DIABETES & METABOLISM, 2007, 33 : S68 - S68
  • [2] Improved cardiometabolic risk in diabetic and non-diabetic overweight/obese patients with rimonabant treatment: data from RIO-Diabetes, RIO-Europe, RIO-North America and RIO-Lipids
    Finer, N.
    Scheen, A. J.
    Despres, J. P.
    Pi-Sunyer, F. X.
    Van Gaal, L.
    DIABETIC MEDICINE, 2007, 24 : 3 - 4
  • [3] Rimonabant improves multiple cardiometabolic risk factors in diabetic and non-diabetic overweight/obese patients: data from RIO-diabetes, RIO-Europe, RIO-North America and RIO-Lipids
    Scheen, A.
    Despres, J. -P.
    Pi-Sunyer, F. X.
    Van Gaal, L.
    EUROPEAN HEART JOURNAL, 2006, 27 : 441 - 441
  • [4] Rimonabant improves oral glucose tolerance in non-diabetic overweight/obese patients with/without comorbidities
    Van Gaal, L. F.
    Despres, J. P.
    Golay, A.
    Rissanen, A.
    DIABETIC MEDICINE, 2007, 24 : 5 - 5
  • [5] Rimonabant improves oral glucose tolerance in non-diabetic overweight/obese patients with/without comorbidities
    Despres, Jean-Pierre
    Van Gaal, Luc
    Glay, Alain
    Rissanen, Aila
    DIABETES, 2006, 55 : A80 - A81
  • [6] Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors:: two year results from the RIO-Europe Study
    Van Gaal, Luc F.
    Scheen, Andre J.
    Rissanen, Aila M.
    Roessner, Stephan
    Hanotin, Corinne
    Ziegler, Olivier
    EUROPEAN HEART JOURNAL, 2008, 29 (14) : 1761 - 1771
  • [7] Efficacy and safety of rimonabant in the management of cardiovascular risk factors: 2-year pooled data from the RIO-Europe and RIO-North America trials
    Van Gaal, L.
    Pi-Sunyer, X.
    EUROPEAN HEART JOURNAL, 2005, 26 : 642 - 642
  • [8] Rimonabant improves glycemic control parameters and glucose tolerance in overweight/obese non diabetic subjects with dyslipidemia.: RIO-Lipids trial
    Golay, A
    Després, J
    Sjöström, L
    DIABETOLOGIA, 2004, 47 : A71 - A71
  • [9] LONG-TERM SAFETY AND EFFICACY OF SELADELPAR IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC): 2-YEAR RESULTS FROM A LONG-TERM STUDY
    Mayo, Marlyn J.
    Vierling, John M.
    Bowlus, Christopher L.
    Neff, Guy W.
    Galambos, Michael R.
    Gordon, Stuart C.
    Borg, Brian
    Levy, Cynthia
    Harrison, Stephen A.
    Thuluvath, Paul J.
    Goel, Aparna
    Shiffman, Mitchell L.
    Steinberg, Alexandra
    Xu, Emily
    Yang, Ke
    Choi, Yun-Jung
    Dickinson, Klara
    McWherter, Charles
    HEPATOLOGY, 2021, 74 : 71A - 73A
  • [10] LONG-TERM INSULIN-TREATMENT IN 2 NON-DIABETIC PATIENTS
    ASPLUND, J
    AHLMARK, G
    GUNNARSSON, R
    OSTMAN, J
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1981, 246 (08): : 870 - 870
12345